Back to blog
    Breaking Study Updates

    Brenipatide Update, November 2026: RENEW-MDD-3, COPD, IBS and the First Journal Review

    20 November 20266 min readBy the Peptx research team

    Brenipatide now has 20 registered studies, including a new phase 2 depression trial and trials in COPD and irritable bowel syndrome. The first journal paper indexed under its name reviews the psychiatric incretin pipeline. What is new and what has not changed.

    Three things have changed for brenipatide since our October post on the RENEW trials. A new depression trial was registered on 10 November 2026. The first journal paper indexed under brenipatide on PubMed has appeared, a review of psychiatric incretin trials. And a fresh read of ClinicalTrials.gov on 20 November 2026 lists 20 studies under brenipatide or its code, LY3537031, against the nine we described in October. Our October list missed five RENEW trials and four phase 1 studies registered under the code. This post covers what is new and corrects the count.

    RENEW-MDD-3: depression with a partial response to treatment

    RENEW-MDD-3 (NCT07928245) is a phase 2, randomised, double-blind, placebo-controlled trial in about 330 adults with major depressive disorder who still have symptoms while taking a stable antidepressant. Brenipatide or placebo is added to the antidepressant. The primary outcome is change on the MADRS, a standard clinician-rated depression scale, at week 10, and participation lasts about five months. Sites are listed in the United States, the United Kingdom and six other European countries.

    That makes it different from the two phase 3 depression trials, RENEW-MDD-1 and RENEW-MDD-2, which enrol people whose depression has eased and measure the time until relapse over a year or more. RENEW-MDD-3 asks the more familiar question for an add-on treatment: whether symptoms improve within weeks.

    The trials missing from our October list

    StudyConditionPhaseParticipantsPrimary completion (registry estimate)
    RENEW-ALC-2Alcohol use disorder and hazardous drinking3About 1,100April 2028
    RENEW-MDD-2Major depressive disorder, time to relapse3About 1,000December 2028
    RENEW-COPDModerate to severe COPD2About 606May 2028
    RENEW-IBS-DIrritable bowel syndrome with diarrhoea2About 531September 2027
    RENEW-IBS-CIrritable bowel syndrome with constipation2About 342July 2027

    RENEW-ALC-2 has the same design and primary outcome as RENEW-ALC-1: change in drinking patterns measured by day-by-day recall over up to 56 weeks. RENEW-COPD measures lung function (FEV1 before a bronchodilator) to week 36. The two IBS trials measure the share of participants with a composite symptom response between weeks 9 and 16.

    Four more phase 1 studies are registered under the code LY3537031: a safety and pharmacokinetic study in about 300 people with overweight or obesity and healthy volunteers (NCT06606106), and studies of how the body absorbs and clears the compound, including in people with reduced kidney or liver function (NCT07165015, NCT07165002, NCT07202871). A twentieth record, a formulation comparison first posted on 10 November 2026, carries a summary that describes an unrelated study, so we have left it out until the registry entry is corrected.

    Why COPD and the bowel?

    The registry records give no rationale. GLP-1 receptor agonists are known to slow stomach emptying and gut transit, which may be one reason to study bowel symptoms, but that is our reading, not the sponsor's. With asthma already in the programme, COPD makes two airway trials. None of these has reported.

    The first journal paper: a review of psychiatric incretin trials

    A review published online on 21 October 2026 in the Journal of Psychiatric Research searched ClinicalTrials.gov on 1 September 2026 for ongoing randomised trials of incretin drugs with a psychiatric or addiction outcome as the primary measure (Fagiolini and Cuomo, 2026). It found:

    • 34 trials planning to enrol 8,519 people, 21 in phase 2 and 6 in phase 3;
    • three compounds behind all of them, with brenipatide among the paper's keywords, and half of the trials testing a co-agonist;
    • alcohol use disorder as the largest target (14 trials), then tobacco or nicotine, opioids and depression;
    • seven trials of one co-agonist from one sponsor making up 62% of planned enrolment. By our count, the brenipatide psychiatric trials registered by that date add up to the same seven trials and 62%.

    The authors conclude that almost all development outside addiction belongs to one sponsor's programme, proceeding without a positive randomised result in any psychiatric condition. They also note that because half the trials use co-agonists, a positive result would not identify which receptor is responsible. We look at that question in GIP and GLP-1 dual agonists in addiction research.

    What has not changed

    • No efficacy result from any brenipatide trial has been published.
    • The only human data remain the phase 1 findings presented at Psych Congress in September 2026: a half-life of 9 to 12 days, and gastrointestinal effects as the most common adverse events at rates comparable to placebo.
    • Brenipatide is not approved anywhere.

    What to watch in 2027

    Registry estimates for primary completion: the smoking relapse trial and the phase 1b obesity study in February, RENEW-IBS-C in July, RENEW-IBS-D in September, and the bipolar disorder and schizophrenia trials in November. The phase 3 alcohol and depression trials are estimated for 2028. Registry dates often move.

    The brenipatide profile now lists every registered study. A Brenipatide 10mg research vial is coming soon to Peptx; join the waitlist on the profile page and we will email you when it lands.

    References

    1. ClinicalTrials.gov. Studies of brenipatide (LY3537031), including NCT07928245, NCT07219953, NCT07775300, NCT07759245, NCT07545759, NCT07545772, NCT06606106, NCT07165015, NCT07165002 and NCT07202871. Records read 20 November 2026. ClinicalTrials.gov
    2. Fagiolini A, Cuomo A. "Incretin-based therapies in psychiatry: A landscape analysis of ongoing randomized trials registered on ClinicalTrials.gov." Journal of Psychiatric Research. 2026. PubMed 42962407
    3. Goldsmith P, Garhyan P, Yan S, et al. Brenipatide, a GIP/GLP-1 receptor agonist: clinical data. Poster, Psych Congress 2026. Reported in Psychiatric Times, 18 September 2026.

    Browse the Peptx catalogue

    Independently tested compounds, typically 99%+ purity (HPLC), factory-direct pricing. UK stock orders placed by 3pm are posted the same day.

    Sold strictly for laboratory research. Not for human consumption.

    Related research

    What net peptide content meansBrowse the research library